Daniel F. Hayes – författare

Oncology: An Evidence-Based Approach is a textbook designed to reflect the principles and current practice of oncology with contributors from the fields of medical, surgical, and radiation oncology. The textbook will incorporate an evidence-based approach, enabling the reader to make decisions on the basis of concrete data. Sections on solid tumors, hematologic malignancies and the practice of oncology address the natural history and therapy for the full spectrum of neoplastic diseases in the adult. Further sections present fundamentals of supportive care of the cancer patient, the management of oncologic emergencies and acute toxicities of therapy, as well as care of metastatic disease and the terminally-ill patient. Breaking new ground, the textbook features thoughtful, in-depth sections on cancer prevention and control, cancer surviorship, the economics of cancer care, and cancer informatics. Cancer imaging is covered with an organ system-based approach, with an additional chapter on the especially intriguing potential of PET.  Furthermore, a comprehensive section on translational basic science reviews the fundamentals of molecular biology, the cell cycle and signal transduction, carcinogenesis, cancer genetics, the biology of invations and metastasis, and tumor immunology.

Oncology: An Evidence-Based Approach is a textbook designed to reflect the principles and current practice of oncology with contributors from the fields of medical, surgical, and radiation oncology. The textbook will incorporate an evidence-based approach, enabling the reader to make decisions on the basis of concrete data. Sections on solid tumors, hematologic malignancies and the practice of oncology address the natural history and therapy for the full spectrum of neoplastic diseases in the adult. Further sections present fundamentals of supportive care of the cancer patient, the management of oncologic emergencies and acute toxicities of therapy, as well as care of metastatic disease and the terminally-ill patient. Breaking new ground, the textbook features thoughtful, in-depth sections on cancer prevention and control, cancer surviorship, the economics of cancer care, and cancer informatics. Cancer imaging is covered with an organ system-based approach, with an additional chapter on the especially intriguing potential of PET.  Furthermore, a comprehensive section on translational basic science reviews the fundamentals of molecular biology, the cell cycle and signal transduction, carcinogenesis, cancer genetics, the biology of invations and metastasis, and tumor immunology.

Expert laboratory and clinical researchers from around the world review how to design and evaluate studies of tumor markers and examine their use in breast cancer patients. The authors cover both the major advances in sophisticated molecular methods and the state-of-the-art in conventional prognostic and predictive indicators. Among the topics discussed are the relevance of rigorous study design and guidelines for the validation studies of new biomarkers, gene expression profiling by tissue microarrays, adjuvant systemic therapy, and the use of estrogen, progesterone, and epidermal growth factor receptors as both prognostic and predictive indicators. Highlights include the evaluation of HER2 and EGFR family members, of p53, and of UPA/PAI-1; the detection of rare cells in blood and marrow; and the detection and analysis of soluble, circulating markers.

Expert laboratory and clinical researchers from around the world review how to design and evaluate studies of tumor markers and examine their use in breast cancer patients. The authors cover both the major advances in sophisticated molecular methods and the state-of-the-art in conventional prognostic and predictive indicators. Among the topics discussed are the relevance of rigorous study design and guidelines for the validation studies of new biomarkers, gene expression profiling by tissue microarrays, adjuvant systemic therapy, and the use of estrogen, progesterone, and epidermal growth factor receptors as both prognostic and predictive indicators. Highlights include the evaluation of HER2 and EGFR family members, of p53, and of UPA/PAI-1; the detection of rare cells in blood and marrow; and the detection and analysis of soluble, circulating markers.